References
- Arellano Y, Bratoeff E, Garrido M, et al. New ester derivatives of dehydroepiandrosterone as 5α-reductase inhibitors. Steroids 2011;76:1241–6
- Bratoeff E, Sánchez A, Arellano Y, et al. In vivo and in vitro effect of androstene derivatives as 5α-reductase type 1 enzyme inhibitors. J Enzyme Inhib Med Chem 2013;28:1247–54
- Garrido M, Cabeza M, Cortés F, et al. Cytotoxic effect of novel dehydroepiandrosterone derivatives on different cancer cell lines. Eur J Med Chem 2013;68:301–11
- Cabeza M, Trejo KV, González C, et al. Steroidal 5α-reductase inhibitors using 4-androstenedione as substrate. J Enzyme Inhib Med Chem 2011;26:712–19
- Bratoeff E, García P, Heuze Y, et al. Molecular interactions of progesterone derivatives with 5α-reductase types 1 and 2 and androgen receptors. Steroids 2010;75:499–505
- Russell DW, Wilson JD. Steroid 5 alpha-reductase: two genes/two enzymes. Annu Rev Biochem 1994;63:25–61
- Imperato-McGinley J, Zhu YS. Androgens and male physiology the syndrome of 5alpha-reductase-2 deficiency. Mol Cell Endocrinol 2002;198:51–9
- Dadras SS, Cai X, Abasolo I, Wang Z. Inhibition of 5alpha-reductase in rat prostate reveals differential regulation of androgen-response gene expression by testosterone and dihydrotestosterone. Gene Expr 2001;9:183–94
- Wright AS, Douglas RC, Thomas LN, et al. Androgen-induced regrowth in the castrated rat ventral prostate: role of 5alpha-reductase. Endocrinology 1999;140:4509–15
- Bosland MC. Chapter 2: the role of steroid hormones in prostate carcinogenesis. JNCI Monographs 2000;2000:39–66
- Raynaud JP. Prostate cancer risk in testosterone-treated men. Proceedings of the 17th International Symposium of the Journal of Steroid Biochemistry and Molecular Biology Recent Advances In Steroid Biochemistry And Molecular Biology (Seefeld, Tyrol); 2006 May 31–June 3;102:261–6; Austria
- Lee HJ, Chang C. Recent advances in androgen receptor action. Cell Mol Life Sci 2003;60:1613–22
- Njar VCO, Klus GT, Brodie AMH. Nucleophilic vinylic “addition-elimination” substitution reaction of 3-acetoxy-17-chloro-16-formylandrosta-5,16-diene: a novel and general route to 17-substituted steroids. Part 1. Synthesis of novel 17-azolyl-Δ16-steroids; inhibitors of 17α-hydroxylase/17,20-lyase (17α -lyase). Bioorg Med Chem Lett 1996;6:2777
- Bradford MM. A rapid and sensitive method for the quantisation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248–54
- Altschul SF, Wootton JC, Gertz EM, et al. Protein database searches using compositionally adjusted substitution matrices. FEBS J 2005;272:5101–9
- Hendry IWJ, Danzo BJ. Structural conversion of cytosolic steroid receptors by an age-dependent epididymal protease. J Steroid Biochem 1985;23:883–93
- Mukherjee A, Kirkovsky LI, Kimura Y, et al. Affinity labelling of the androgen receptor with nonsteroidal chemoaffinity ligands. Biochem Pharmacol 1999;58:1259–67
- Bull HG, Garcia-Calvo M, Andersson S, et al. Mechanism-based inhibition of human steroid 5α-reductase by finasteride: enzyme-catalyzed formation of NADP-dihydrofinasteride, a potent bisubstrate analog inhibitor. J Am Chem Soc 1996;118:2359–65
- Warren MS, Marolewski AE, Benkovic SJ. A rapid screen of active site mutants in glycinamide ribonucleotide transformylase. Biochemistry 1996;35:8855–62
- Desharnais J, Hwang I, Zhang Y, et al. Design, synthesis and biological evaluation of 10-CF3CO-DDACTHF analogues and derivatives as inhibitors of GAR Tfase and the de novo purine biosynthetic pathway. Bioorg Med Chem 2003;11:4511–21
- Christopherson RI, Lyons SD, Wilson PK. Inhibitors of de novo nucleotide biosynthesis as drugs. Acc Chem Res 2002;35:961–71
- Graham LP. Medicinal chemistry. Oxford: Oxford University Press; 2001, 226–53
- Heck HD, Casanova M, Starr TB. Formaldehyde toxicity-new understanding. Crit Rev Toxicol 1990;20:397–426